A study has found that the majority of kidney cancer patients with small tumors have their entire kidney removed, which can increase the risk of developing chronic kidney disease and cardiovascular complications.

Our experts have participated in or led the development of five of the seven drugs approved by the US Food and Drug Administration for patients with advanced kidney cancer since 2005.

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

Dr. Dalbagni – who cares for patients with bladder cancer, kidney cancer, penile cancer, and sarcomas – explains treatments offered at Memorial Sloan-Kettering, which can help patients maintain their quality of life.

Dr. Douer, leader of the research program in acute lymphoblastic leukemia, talks about how patients are treated by a caring team that includes physicians, nurses, social workers, and support staff.

Early research led by investigators at Memorial Sloan-Kettering cautions against combining ipilimumab and vemurafenib for the treatment of metastatic melanoma.

Dr. Sonoda, who performs minimally invasive procedures when possible, discusses how patients at Memorial Sloan-Kettering have the benefit of an entire team of physicians having input into their care.